替考拉宁与万古霉素及利奈唑胺治疗MRSA感染患者的疗效评价

发布时间：2018-04-19 10:11

本文选题：替考拉宁 + 万古霉素　；参考：《中华医院感染学杂志》2015年17期

【摘要】：目的评价替考拉宁、万古霉素及利奈唑胺治疗ICU耐甲氧西林金黄色葡萄球菌(MASA)感染的疗效与安全性。方法选取2013年5月-2014年7月入住医院的96例ICU MRSA重症感染患者,将其随机分为3组,替考拉宁组33例、万古霉素组32例、利奈唑胺组31例,比较3组患者的临床疗效、细菌清除率及不良反应发生率。结果替考拉宁、万古霉素及利奈唑胺治疗MASA感染患者的临床有效率分别为87.88%、81.25%、87.10%,细菌清除率分别为84.85%、81.25%、83.87%,不良反应发生率分别为6.06%、12.50%、9.68%,临床有效率及细菌清除率3组对比差异无统计学意义;不良反应发生率3组对比差异有统计学意义(P0.05)。结论替考拉宁、万古霉素和利奈唑胺治疗ICU MRSA感染的临床疗效可靠,替考拉宁的不良反应较少,治疗时可优先选择替考拉宁。
[Abstract]:Objective to evaluate the efficacy and safety of teicoplanin, vancomycin and linazolamide in the treatment of ICU methicillin-resistant Staphylococcus aureus infection.Methods 96 patients with severe ICU MRSA infection admitted to hospital from May 2013 to July 2014 were randomly divided into three groups: teicoplanin group (33 cases), vancomycin group (32 cases) and linazolidomide group (31 cases).Bacterial clearance rate and adverse reaction rate.Results the clinical effective rates of teicoplanin, vancomycin and linazolamine in the treatment of MASA infection were 87.88 and 81.25, respectively. The bacterial clearance rates were 84.85 and 81.253.87.The incidence of adverse reactions were 6.06 ~ 12.50 and 9.68, respectively. There was no significant difference in the clinical effective rate and bacterial clearance rate among the three groups.The incidence of adverse reactions was significantly different among the three groups (P 0.05).Conclusion teicoplanin, vancomycin and linazolamine are effective in the treatment of ICU MRSA infection, and the adverse reactions of teicoplanin are less.
【作者单位】：郑州大学第二附属医院重症医学科;郑州人民医院急诊科;
【基金】：河南省重点科技攻关基金资助项目(132102310391)
【分类号】：R515

【共引文献】